Status:
COMPLETED
Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC
Lead Sponsor:
Gachon University Gil Medical Center
Conditions:
Advanced Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To evaluate the toxicity and efficacy of docetaxel and cisplatin combination on two schedules in patients with previously untreated, advanced NSCLC.
Detailed Description
The combination of docetaxel 75 mg/m2 and cisplatin 60-80 mg/m2 administered every 3 weeks is one of the most commonly used chemotherapy regimen in Korea for the first-line treatment of advanced NSCLC...
Eligibility Criteria
Inclusion
- histologically or cytologically proven non-small cell lung cancer
- no prior chemotherapy or only adjuvant chemotherapy which had been completed \>6 months before registration
- ECOG performance status 0 to 2
- measurable lesion(s)
- normal marrow, hepatic and renal functions
- provision of written informed consent
Exclusion
- active infection or severe comorbidities
- history of anaphylaxis of any origin
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00319514
Start Date
April 1 2004
End Date
October 1 2006
Last Update
March 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gachon University Gil Medical Center
Incheon, South Korea, 405 760